AzTrials
AzTrials

Peripheral Arterial DiseaseAxys ACHIEVENCT04282161

Pivotal Study of the Medtronic Axys EX Rotational Atherectomy System

A study testing Axys EX device in people with Peripheral Arterial Disease, run by Medtronic Endovascular.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The primary objective is to demonstrate the safety and effectiveness of the Axys EX rotational atherectomy system in subjects with peripheral arterial disease who have de novo or non-stented restenotic obstructive lesions in the peripheral vasculature of the lower limbs. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Peripheral Arterial Disease
What is being tested?
Axys EX device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
Dec 2021to Feb 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

General Inclusion Criteria:

  1. Rutherford Clinical Category (RCC) Score of 2 - 5
  2. Willing and capable of complying with all follow-up evaluations at the specified times
  3. Age ≥ 18 years old
  4. Provides written informed consent prior to study specific procedures
  5. Completed Ankle/Brachial Index (ABI) (or Toe/Brachial Index [TBI]) prior to index procedure (up to 60 days prior) Angiographic Inclusion Criteria:
  6. Evidence of ≥ 70% stenosis or occlusion in the peripheral vasculature of the target vessel, confirmed by angiography
  7. Target lesion present in a single limb that consists of a single de novo or non-stented restenotic lesion, or qualifies as a tandem or combination lesion per the definitions below:
  8. Tandem (adjacent) Lesion: Lesions present in the same target vessel that can be treated as one single lesion and is separated by an angiographic normal vessel ≤3 cm at any point. Multiple points of separation can be present in single lesion treatment if no single point of separation is > 3 cm
  9. Combination Lesion: A single lesion that is not completely occluded but includes a segment of complete occlusion anywhere along the length
  10. Exchangeable guidewire must cross target lesion within the lumen
  11. Total target lesion length is ≥ 20 mm and ≤ 200mm
  12. Reference vessel diameter (RVD) is ≥ 2.0 mm and ≤ 5.0 mm
  13. Identifiable distal target vessel which upon completion of the intervention is anticipated to provide reconstitution of blood flow to the foot. Angiographic evidence of adequate distal runoff through the foot (at least one native calf vessel [posterior tibial, anterior tibial, or peroneal artery] is patent, defined as < 50% stenosed)
  14. Multiple lesions in the target limb (including the target lesion and non-target lesions) may be treated if all of the following applies:
  15. Non-target lesion(s) must be located proximal to the target lesion
  16. Non-target lesion(s) must be successfully treated (defined as optimally treated [e.g. no untreated arterial dissections or perforation present]) by standard endovascular procedures prior to initiation of treatment of the target lesion
  17. Non-target lesions treated prior to target lesion cannot be treated with rotational, orbital or laser atherectomy
  18. Non-target lesion(s) may be located in separate vascular beds (i.e., iliac,femoropopliteal, tibial) or multiple tibial vascular beds (i.e., anterior tibial, posterior tibial, tibioperoneal trunk/peroneal). (Note: Only one tibial vessel may be identified as the target vessel with the target lesion.)
  19. Only one lesion per the above definitions may be treated as the target lesion with the Axys EX device General Exclusion Criteria:
  20. Has one or more of the contraindications listed in the Axys EX Rotational Atherectomy System's IFU
  21. Contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs, or any other drug anticipated to be used
  22. Hypersensitivity to contrast material that cannot be adequately pretreated
  23. Known uncontrollable hypercoagulable condition or refuses blood transfusion
  24. Life expectancy of less than 12 months
  25. Surgical (requiring hospitalization) or endovascular intervention of the target limb within 30 days prior to the index procedure
  26. Planned surgical intervention or endovascular procedure within 30 days after the index procedure
  27. Currently participating in an investigational drug or another device study that may clinically interfere with the study endpoints
  28. Other co-morbid condition(s) that in the judgment of the physician precludes safe percutaneous intervention
  29. If a previous peripheral bypass affecting the target limb is present, the bypass must be patent and the target lesion cannot be present in the peripheral bypass artery
  30. Impaired renal function (defined as GFR < 30 mL/min) or on dialysis
  31. Recent myocardial infarction or stroke ≤ 30 days prior to the index procedure
  32. Previous or planned amputation above the metatarsal line on the target limb
  33. Patient belongs to a vulnerable population per investigator's judgment or patient has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures. Patient must be able to consent for themselves
  34. Patient is pregnant (female patients of child-bearing potential must have a pregnancy test done within 7 days prior to the index procedure) Angiographic Exclusion Criteria:
  35. Noted thrombus at the point of the intended target lesion
  36. In-stent restenosis of the target lesion
  37. Aneurysmal target vessel
  38. Hemodynamic significant stenosis or occlusion of inflow tract that has not been revascularized prior to treatment of the target vessel
  39. Perforation, flow limiting dissection or other injury of the target vessel requiring surgical intervention prior to enrollment
  40. Disease that precludes safe advancement of the Axys EX device to the target lesion
  41. Need to treat a lesion distal to the target index lesion

About this study

Official title: Pivotal Study of the Medtronic Axys EX Rotational Atherectomy System for the Treatment of Peripheral Arterial Disease in the Vasculature of the Lower Limbs

The primary objective is to demonstrate the safety and effectiveness of the Axys EX rotational atherectomy system in subjects with peripheral arterial disease who have de novo or non-stented restenotic obstructive lesions in the peripheral vasculature of the lower limbs.

Being tested
Axys EX device
Keywords
Peripheral Vascular Disease, Critical Limb Ischemia, Superficial Femoral Artery Stenosis, Atherosclerosis, Arteriosclerosis, Vascular Diseases, Arterial Disease Occlusive, lower extremity arterial disease
Medical subject headings
Peripheral Arterial Disease, Peripheral Vascular Diseases, Chronic Limb-Threatening Ischemia, Atherosclerosis, Arteriosclerosis, Vascular Diseases, Arterial Occlusive Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Axys EX deviceDevice

    Also called Axys EX

    Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed

Study groups in NCT04282161
Study groupRoleWhat they receive
Axys EX deviceExperimentalNot described
Receives: Device: Axys EX device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Effectiveness

    Change in percent stenosis in the treatment vessel. Percent stenosis is defined as native vessel diameter as measured at the narrowest point of the lesion divided by the estimated native vessel diameter at that location.

    Measured: During procedure

  2. Primary Safety

    Major Adverse Events (MAEs) at 30 Days post-procedure defined as freedom from clinically-driven target lesion revascularization (CD-TLR), major unplanned amputation of the treated limb, or all-cause mortality.

    Measured: 30-Days

Secondary outcomes (16)
  1. Technical Success

    Defined as the ability of the Axys EX device to successfully traverse/cross the entire intended length of the target lesion

    Measured: During Procedure

  2. Procedural Success

    Defined as ≤ 30% residual stenosis following use of the Axys EX device and adjunctive therapy as measured by angiography and determined by the angiographic core laboratory

    Measured: During Procedure

  3. Amputation-Free Survival

    Defined as freedom from a major, unplanned amputation of the target limb through the 12 month visit

    Measured: 12-Months

  4. Major Adverse Events (MAEs)

    Defined as freedom from clinically-driven target vessel revascularization (CD-TVR), major unplanned amputation of the treated limb, thrombosis at the target lesion site, or all-cause mortality

    Measured: 12-Months

  5. Rate of Target Lesion Revascularization (TLR)

    Any re-intervention at the target lesion

    Measured: 6 and 12-Months

  6. Rate of Target Vessel Revascularization (TVR)

    Any re-intervention within the target vessel

    Measured: 6 and 12-Months

  7. Provisional Stent Rate

    Measured: During Procedure

  8. Flow Limiting Dissection

    Target lesion flow limiting dissection (D or greater) rate after adjunctive therapy

    Measured: During Procedure

  9. Primary Patency as determined by Duplex Ultrasound (DUS)

    1. For subjects with a target lesion in the femoropopliteal region (above the knee [ATK]) through the level of popliteal segment P3 (below the knee popliteal artery from the center of the knee joint space to the origin of anterior tibial artery), primary patency is defined as freedom from core laboratory-assessed restenosis (DUS PSVR ≤2.4) and CD-TLR (adjudicated by a Clinical Events Committee)
    2. For subjects with a target lesion below the level of popliteal segment P3 (below the knee [BTK]), primary patency is defined as freedom from core laboratory-assessed absence of target lesion occlusion (no flow) as assessed by DUS and CD-TLR (adjudicated by a Clinical Events Committee)

    Measured: 6 and 12-Months

  10. Quality of Life Assessment

    EQ-5D questionnaire

    Measured: 30-Days, 6 and 12-Months

  11. Walking Distance

    6-Minute Walking Test

    Measured: 30-Days, 6 and 12-Months

  12. Walking Capacity

    Walking Impairment Questionnaire (WIQ)

    Measured: 30-Days, 6 and 12-Months

  13. Ankle/brachial index (ABI) or toe/brachial index (TBI)

    Measured: 30-Days, 6 and 12-Months

  14. Rutherford clinical category (RCC)

    Measured: 30-Days, 6 and 12-Months

  15. Distal Embolization in Target Limb

    Clinically significant distal embolization in target limb within 30 days defined as distal embolization requiring treatment by mechanical or pharmacologic means (other than a vasodilator) (adjudicated by a Clinical Events Committee)

    Measured: 30-Days

  16. Major Vessel Perforation

    requiring surgical or endovascular repair within 30 days (adjudicated by a Clinical Events Committee) 6.

    Measured: 30-Days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2020
  2. Study startDec 2021 (estimated)
  3. Primary completionAug 2023 (estimated)
  4. Study completionFeb 2024 (estimated)

Why it stopped: Business Decision

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04282161
Sponsor's protocol ID
MDT17045
Acronym
Axys ACHIEVE
Status last verified
Mar 2021
First submitted
18 Feb 2020
Last updated
5 Apr 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Axys EX device in people with Peripheral Arterial Disease, run by Medtronic Endovascular.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 5 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Effectiveness (time frame: During procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in